Editorial: The impact of microbiota and cytokines on inflammatory bowel disease.
Kanauchi
Osamu
O
Mitsuyama
Keiichi
K
D000818:Animals; D003474:Curcumin / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000209:etiology / Q000378:metabolism* / Q000382:microbiology* / Q000628:therapy; D015850:Interleukin-6 / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology; D007937:Leukapheresis / Q000295:instrumentation / Q000379:methods; D008263:Macrophage Migration-Inhibitory Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000093242:Interleukin-6 Inhibitors
D003474:Curcumin; D016207:Cytokines; D015850:Interleukin-6; D008263:Macrophage Migration-Inhibitory Factors; D000093242:Interleukin-6 Inhibitors